The impact of detoxification on suicidal behaviour among heroin users: longitudinal data from South Africa

> Dr Nirvana Morgan MD, Mmed, FCPsych, PhD Alexander Von Humboldt Postdoctoral Fellow Ulm University

- No COI
- Acknowledgments:
 - Alexander von Humboldt Institute
 - M and J Miller Foundation
 - South African National Research Foundation



Alexander von Humboldt Stiftung/Foundation



Background

WITS NYAOPE STUDY

Udaba lwakho lubalulekile. SIFUNA UKULALELA.

BAHLANGANYELI ABAKHETHEKILE

Sikwamukela kucwaningo lase Wits leNyaope! Siyajabula ukuthi uvumile ukusebenza nathi. Ukuze lolucwaningo lube yimpumelelo nakhu ongakwenza.

Kuzoqala kube nomhlangano kwi-rehab yakho.

Kubalulekile sikubone emva kwezinyanga ezingu-3 nezingu-9

Sizokushayela ucingo sikukhumbuze ukuthi sizohlangana nini.

Sicela usazise uma izinombolo zakho zocingo zishintsha.




SITHOLAKALA KANJE: Ungasishayela ucingo, noma usithumele i-SMS, noma usithumele i-Whatsapp kulenombolo 0837678287




WITS NYAOPE STUDY 2017-2020 YOUR STORY MATTERS. WE WANT TO LISTEN. ALL YOU NEED TO DO IS TELL US ABOUT YOUR JOURNEY. IF YOU WOULD LIKE TO JOIN PLEASE ASK TO SPEAK WITH DR MORGAN CONTACT NUMBER: 083 767 8287 UNIVERSITY OF THE

JOHANNESBURG

Nyaope- what is it?







Objectives

- To describe the treatment outcomes of heroin users who attend inpatient detoxification and psychosocial rehabilitation.
- The variables that were assessed were
 - changes in substance use
 - injecting and sexual behaviour
 - social functioning
 - criminality
 - mental illnesses
 - general health

SUICIDAL IDEATION AND BEHAVIOUR





Longitudinal Patterns of Suicidality Among Heroin Users in Johannesburg, South Africa: A Need for Suicide Screening and Intervention

Nirvana Morgan^{1*}, Ellen-ge Denton², Ugasvaree Subramaney³, William Daniels⁴ and Tilman Steinert¹

¹ Department of Psychiatry, Ulm University, Ulm, Germany, ² Department of Psychology, College of Staten Island, City University of New York, New York, NY, United States, ³ Department of Psychiatry, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa, ⁴ School of Physiology, University of the Witwatersrand, Johannesburg, South Africa


Methods





2 x in-patient rehabilitation facilities1 week of detoxification4-6 weeks of psychosocial rehabilitation











Methods

Before detox	3-months after detox	9-months after detox	
300 nyaope users	252 (84%)	225 (75%)	
ΟΤΙ	Follow-up interview	Follow-up interview	
MINI	OTI MINI MDUT	OTI MINI MDUT	

	B. SUICIDALITY			
	In the past month did you:			Points
B1	Have any accident? This includes taking too much of your medication accidentally. IF NO TO B1 , SKIP TO B2 . IF YES, ASK B1a :	NO	YES	0
B1a	Plan or intend to hurt yourself in any accident, either by not avoiding a risk or by causing the accident on purpose?	NO	YES	0
	IF NO TO B1a , SKIP TO B2 . IF YES, ASK B1b :			
B1b	Intend to die as a result of any accident?	NO	YES	0
B2	Think (even momentarily) that you would be better off dead or wish you were dead or needed to be dead?	NO	YES	1
В3	Think (even momentarily) about harming or of hurting or of injuring yourself - with at least some intent or awareness that you might die as a result - or think about suicide (i.e. about killing yourself)?	NO	YES	6
	IF NO TO B2 + B3 , SKIP TO B4 . OTHERWISE ASK:			
	Frequency Intensity			
	OccasionallyImage: MildOftenModerateVery oftenSevere			
B4	Hear a voice or voices telling you to kill yourself or have dreams with any suicidal content? IF YES, mark either or both:	NO	YES	4
B5	Have a suicide method in mind (i.e. how)?	NO	YES	8




TABLE 1 | Clinical characteristics over 9-months.

	Baseline (n-300)		t1 (n–252)		t2 (n–225)	
	N	%	N	%	N	%
Past month substance use						
Heroin	300	100	165	65.5	163	72.4
Cannabis	259	86.3	184	73.0	185	82.2
Crack/Cocaine	78	26.0	43	17.1	51	22.7
Crystalmetamphetamine	58	19.3	59	23.4	46	20.4
Methaqualone	55	18.3	43	17.1	47	20.9
Alcohol	49	16.3	139	55.2	103	45.8
≥3 substances used	162	54.0	128	50.8	132	58.7
Diagnosis of a mental illness (excluding ASPD)	148	49.3	103	40.9	84	37.3
ASPD	157	52.3				
Median Social functioning score (IQR)	27 (22.5–31)		23 <mark>(</mark> 19–27)	23 (19–27)		
Median General health score (IQR)	7 (5–8)		4 (2–7)		6 (3–8)	
Median injecting and sexual behavior score (IQR)	5 (0–12)		3 (0–6)		4 (2–8)	
Median criminality score (IOR)	4 (1–6)		0 (0–2)		0 (0–3)	
SIB (score > 0)	*206	68.7	98	38.9	**106	47.1

*Baseline vs. t1: p = 0.0049, **t1 vs. t2: p = 0.031.

TABLE 2 | Categories of SIB over 9-months.

	Baseline n = 206 (%)	t1 n = 98 (%)	t2 n = 106	<i>p</i> -value (baseline vs. t1)	<i>p</i> -value (t1 vs. t2)	<i>p</i> -value (baseline vs. t2)
Low score (1–7)	41 (19.9)	28 (28.6)	34 (32.1)			
Moderate score (8–16)	10 (4.9)	11 (11.2)	10 (9.4)			
High score (≥17)	155 (75.2)	59 (60.2)	62 (58.5)	*<0.0001	*0.43	*<0.0001
Past month suicidality	200 (66.7)	93 (37.1)	100 (44.4)	<0.0001	0.056	<0.0001
Suicide likely in following 3 months	26 (8.7)	41 (16.3)	51 (22.7)	0.0049	0.031	<0.0001

*Comparison between a high score and low/moderate score.

FACTORS ASSOCIATED WITH A HIGH SIB SCORE AT BASELINE

Multivariable analysis					
Variable	<i>p</i> -value	RR for high SIB score			
		RR	95% CL for RR		
Mental illness	<0.0001	1.63	1.30–2.03		
Median general health score (RR is per point)	0.001	1.02	1.01-1.04		

FACTORS ASSOCIATED WITH A HIGH SIB SCORE AT T2 (9 Months)

Multivariable analysis				
Variable	<i>p</i> -value	RR for high t2 SIB score		
		RR	95% CL for R	
Mental illness at t1	<0.0001	2.73	1.78–4.19	
Baseline social functioning score: median (IQR)(RR is per point)	<0.0001	1.07	1.04–1.11	

Results summary

- 68.7% endorsed SIB at baseline
- An initial decrease in SIB at 3 months was followed by an increase at 9 months
- 44.4% endorsed SIB at 9 months
- Any mental illness, social functioning, and general health increased the RR of SIB

How does SA compare to other countries?

- Studies from high-income regions report a SIB prevalence of 22.5%- 33% among heroin users at baseline.
- In comparison, our study findings show that 68.7% endorsed SIB at baseline.

Darke S, et al Drug Alcohol Depend. (2007) 87:146–52. doi: 10.1016/j.drugalcdep.2006.08.010, Hubbard RL, et al. Psychol Addict Behav. (1997) 11:261–78.doi:10.1037/0893-164X.11.4.261, Gossop M, et al. Addict Behav. (2002) 27:155–66. doi: 10.1016/S0306-4603(00)00174-X

How does SA compare to other countries?

- In our cohort, 68.7% reported past month SIB at baseline and 44.4 % at 9-month follow-up.
- ATOS : 387 heroin users 22.5% reported current suicidal ideation at baseline and 6.7% at 12month follow-up
- There were no substantial differences between the South African cohort and the Australian cohort in terms of average age of participants (27 vs. 29.4 y), years of education (10-11 vs. 10.2y), age of onset of heroin use (19 vs. 18y) and length of heroin use (7 y in both cohorts).

Where are the gaps?

- The treatment system
 - Detoxification-based model
 - Disintegrated and fragmented
- Lack of screening
- Untreated psychiatric and general medical comorbidities

What can be done to mitigate suicide risk?

- Heightened awareness of risks in the first year of "recovery"
- Suicide screening tools
 - Created for a SUD population
 - Inform actionable clinical risk
 - Validated in LAMIC population groups
 - ? Digital interventions
- OAMT
- Screen and treat psychiatric and non-psychiatric comorbidities
- Enhance social support: integration programs, skills development, family support